ProKidney Corp.

ProKidney Corp.

PROK·NASDAQ

$1.73

-8.9%
HealthcareBiotechnology

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

At a Glance

Live Snapshot
Market Cap$581.72M
EPS-0.5200
P/E Ratio-3.33
Earnings Date08/06/2026

No Dividend Yield Data

PROK has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

PROK has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

PROK has not reported any net dividends paid values in the available annual periods.

ProKidney Corp.

ProKidney Corp. Dividend History

PROK · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

PROK Dividend Payment History

PROK · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
prok

ProKidney Corp. Payout Ratio Analysis

PROK · NASDAQ
Dividends Paid
0.00
2025
Net Income
-68.99M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.